https://www.selleckchem.com/pr....oducts/Fedratinib-SA
95% CI, 1.08-1.71]), receiving a regimen with high FN risk (commercial insurance aOR, 16.01 [95% CI, 15.17-16.90]; Medicare aOR, 17.17 [95% CI, 15.76-18.71]), and history of neutropenia (commercial insurance 3.90 (3.67-4.15); Medicare 3.82 (3.50-4.18). This cross-sectional study found that utilization of G-CSFs increased among patients with cancer with high FN risk in both a commercially and Medicare-insured population, but 14% to 17% of patients still did not receive preventive treatment. This cross-sectional stud
Mi piace
Commento
Condividi
